233772-16-2

Basic information

• Product Name: methyl(4-nitrophenethyl)sulfane
• Synonyms: methyl(4-nitrophenethyl)sulfane
• CAS NO: 233772-16-2
• Molecular Weight: 197.258
• Mol File: 233772-16-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl(4-nitrophenethyl)sulfane(CAS DataBase Reference)
• NIST Chemistry Reference: methyl(4-nitrophenethyl)sulfane(233772-16-2)
• EPA Substance Registry System: methyl(4-nitrophenethyl)sulfane(233772-16-2)

Safety Data

• Hazardous Substances Data: 233772-16-2(Hazardous Substances Data)

Upstream product

• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 5188-07-8 sodium thiomethoxide 
• 100-13-0 4-nitrostyrene 
• 85055-60-3 dimethyl-(methylthio)-sulphonium trifluoromethanesulphonate 

Downstream Products

• 596131-24-7 4-(2-methanesulfonyl-ethyl)-aniline 
• 1027357-11-4 methyl-(4-nitro-phenethyl)-sulfone 

Relevant articles and documents

Transition metal-free formal hydro/deuteromethylthiolation of unactivated alkenes

Methylthioether is involved in the methylthiotransfer process in organisms, and therefore its functionality is of paramount importance to living organisms. Several methods for the installation of the methylthio group in small molecules have been reported previously; however, procedures starting from unactivated alkenes are rare. Herein, we report a formal hydro/deuteromethylthiolation of alkenes by using dimethyl(methylthio)sulfonium trifluoromethanesulfonate as the stimulator and sodium borohydride/deuteride as the hydrogen/deuterium source. The process represents a mild, transition metal-free and methanethiol-free route towards the synthesis of methylthioethers from unactivated alkenes. This journal is

Treatment Method

The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Combination therapies for the treatment of ocular neovascular disorders are also encompassed.

CHEMICAL PROCESS

A process for the preparation of pyrimidine derivatives, which are useful as VEGFR2 inhibitors is described herein. The described invention also includes pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.